Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2025 / May / Fluid Biomarker Assay Detects Early-Stage Parkinson’s
Neurology Research and Innovations Analytical science

Fluid Biomarker Assay Detects Early-Stage Parkinson’s

A test for a misfolded protein shows viability for Parkinson’s and MSA diagnosis

05/06/2025 News 2 min read

Share

Researchers in Germany have identified a fluid biomarker for detecting Parkinson’s disease (PD) and multiple system atrophy (MSA) by measuring changes in a key brain protein.

Using a platform called the immuno-infrared sensor (iRS), researchers tested spinal fluid samples from 134 individuals and correctly identified PD and MSA cases with 97 percent sensitivity and 92 percent specificity​.

The iRS test looks at the shape of the alpha-synuclein (αSyn) protein, which changes as PD and MSA develop. Normally, αSyn has a flexible structure, but in disease, it forms a more rigid, folded shape. The researchers measured this shift directly without needing special labels or chemical changes​.

Samples came from two groups of patients: one group with 59 people (17 with PD, 42 controls), and the other with 75 people (40 with PD, 5 with MSA, and 30 with other brain disorders). The test measured changes in the protein’s structure and found that disease cases had a significant shift compared to controls​.

The overall accuracy of the test was strong: it achieved an area under the curve of 0.90, correctly distinguishing patients from controls almost all the time​. Researchers also divided results into three groups – low, intermediate, and high likelihood of disease – to better track those who might develop PD or MSA in the future​.

Among those with damage to the blood–brain barrier, a marker of brain injury, 79 percent of patients tested positive for misfolding, compared to none of the healthy controls​.

Unlike existing tests that only detect certain types of damaged protein, the iRS approach measures all forms, offering a broader picture of disease activity. The method also showed superior accuracy than using age and sex alone to predict disease​.

The researchers plan to refine the device for ease of use  in clinical practice​. While larger studies are still needed, these results suggest that measuring alpha-synuclein shape changes directly could help doctors diagnose PD earlier and more accurately​.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Global Referral
Research and Innovations
Global Referral

January 12, 2024

10 min read

How digital pathology is transforming the delivery of remote second opinions

Research Roundup
Research and Innovations
Research Roundup

January 31, 2024

1 min read

From spatial transcriptomics to AI diagnosis, we bring you the latest news in pathology and laboratory medicine

Flexible Solutions With FlexVUE
Research and Innovations
Flexible Solutions With FlexVUE

December 29, 2021

1 min read

Quickly customize your immune panels with Ultivue’s new innovation

Defining the Next Generation of NGS
Research and Innovations
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.